Jason Harris


Immunotherapy/TKI frontline combo lowers need for subsequent therapy in advanced renal cell carcinoma

November 21, 2022

Findings shared during the 2022 International Kidney Cancer Symposium showed that patients with advanced renal cell carcinoma treated upfront with pembrolizumab plus lenvatinib were far less likely to need second-line therapy vs patients receiving first-line sunitinib.